Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gynecologic 1

Conditions

Ovarian Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Endometrial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Peritoneal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Platinum-resistant Recurrent Ovarian Cancer 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Pancreatic Ductal 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × tremelimumab × Gynecologic × Clear all
NCT03015129 2024-02-06

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
80 enrolled 9 charts
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡